<DOC>
	<DOCNO>NCT02305472</DOCNO>
	<brief_summary>The NeoVas Bioresorbable Coronary Scaffold Registry Trial prospective , multi-center , single arm registry trial base NeoVas FIM study verify safety effectiveness NeoVas initially . This study evaluate safety effectiveness NeoVas sirolimus-eluting bioresorbable coronary scaffold treatment patient de novo coronary lesion .</brief_summary>
	<brief_title>NeoVas Bioresorbable Coronary Scaffold Registry Study</brief_title>
	<detailed_description>Approximately 825 subject enrol receive NeoVas BCS ( Lepu Medical Technology ( Beijing ) Co. , Ltd ) . Subjects clinical follow-up 30 , 90 , 180 270 day 1,2,3,4 5 year . The primary endpoint target lesion failure ( TLF ) 1 year follow-up .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Age must 1875 year , men unpregnant woman . Patient must evidence myocardial ischemia , suitable elective PCI . Subjects stable angina silent ischemia &lt; 70 % diameter stenosis must objective sign ischemia determine one following , echocardiogram , nuclear scan , ambulatory ECG stress ECG . In absence noninvasive ischemia , fractional flow reserve ( FFR ) must do indicative ischemia . Patients one two de novo lesion locate different epicardial vessel . Target lesion must be≤20mm length ( visual estimation ) 2.75 3.75 mm diameter ( Online QCA ) . Target lesion visually estimate stenosis ≥70 % ( or≥50 % evidence myocardial ischemia ) TIMI flow ≥1 . The target lesion cover one scaffold ( except rescue scaffold ) . Patient must acceptable candidate coronary artery bypass graft . Patient legally authorize representative must provide write Informed Consent prior study related procedure . Patients know diagnosis acute myocardial infarction ( AMI ) within 7 day precede procedure ; CK CKMB return within normal limit time procedure . Chronic total occlusion lesion ( TIMI 0 grade blood flow prior implantation ) , leave trunk vessel lesion , ostial lesion , multibranch lesion need treat , bifurcation lesion ( diameter ≥2.0mm , branch open stenosis exceed 50 % need balloon expansion ) bridge vessel lesion ; thrombus visible target blood vessel . Severe calcify lesion twisted lesion preexpanded , lesion unsuitable deliver expand stent . Instent restenosis lesion . Patient undergone previous stenting anywhere within target vessel ( ) within previous 12 month , require stenting within target vessel ( ) within 1 year study procedure ; target vessel implant stent . Severe heart failure ( NYHA III grade ) , leave ventricular ejection fraction ( LVEF ) &lt; 40 % ( supersonic inspection leave ventricular radiography ) . Known renal insufficiency ( eGFR &lt; 60 ml/min , serum creatinine &gt; 2.5mg/dL , subject dialysis ) . Patients hemorrhage tendency , active digestive ulcer history , cerebral hemorrhage subarachnoid hemorrhage history , cerebral apoplexy within half year , patient contraindicate platelet inhibitor anticoagulant therefore bear anticoagulation treatment . Patient known hypersensitivity contraindication aspirin , clopidogrel , ticagrelor prasugrel , heparin , contrast agent , polylactic acid sirolimus adequately premedicated . Life expectancy &lt; 12 month . Patient participate another device drug study reach primary endpoint study . Patient 's inability fully cooperate study protocol . Patient heart transplant . Patient current unstable arrhythmia , high risk ventricular premature beat ventricular tachycardia . Patient receive schedule receive chemotherapy malignancy within 30 day prior procedure . Patient receive immunosuppression therapy know immunosuppressive autoimmune disease . Patient receive schedule receive chronic anticoagulation therapy ( e.g. , heparin , warfarin ) . Elective surgery plan within first 6 month procedure require discontinue either aspirin , clopidogrel , ticagrelor prasugrel . Platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 , WBC &lt; 3,000 cells/mm3 , document suspect liver disease . Patient extensive peripheral vascular disease precludes safe 6 French sheath insertion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>NeoVas</keyword>
	<keyword>Bioresorbable Coronary Scaffold</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Registry Trial</keyword>
</DOC>